Cite
Tipifarnib in Head and Neck Squamous Cell Carcinoma With HRAS Mutations.
MLA
Ho, Alan L., et al. “Tipifarnib in Head and Neck Squamous Cell Carcinoma With HRAS Mutations.” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, vol. 39, no. 17, June 2021, pp. 1856–64. EBSCOhost, https://doi.org/10.1200/JCO.20.02903.
APA
Ho, A. L., Brana, I., Haddad, R., Bauman, J., Bible, K., Oosting, S., Wong, D. J., Ahn, M.-J., Boni, V., Even, C., Fayette, J., Flor, M. J., Harrington, K., Kim, S.-B., Licitra, L., Nixon, I., Saba, N. F., Hackenberg, S., Specenier, P., … Gualberto, A. (2021). Tipifarnib in Head and Neck Squamous Cell Carcinoma With HRAS Mutations. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 39(17), 1856–1864. https://doi.org/10.1200/JCO.20.02903
Chicago
Ho, Alan L, Irene Brana, Robert Haddad, Jessica Bauman, Keith Bible, Sjoukje Oosting, Deborah J Wong, et al. 2021. “Tipifarnib in Head and Neck Squamous Cell Carcinoma With HRAS Mutations.” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 39 (17): 1856–64. doi:10.1200/JCO.20.02903.